Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis AG Common Stock
(NY:
NVS
)
109.59
+1.13 (+1.04%)
Official Closing Price
Updated: 7:00 PM EDT, May 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
45
46
Next >
AI for Pharma and Biotech Market Giants Spending Is Going to Boom : PFIZER, Abbott, SANOFI, Atomwise
May 09, 2023
Stay up-to-date with AI for Pharma and Biotech Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
May 09, 2023
Via
Benzinga
Regeneron Pharma Dives As Competition Undercuts Its Biggest Moneymaker
May 04, 2023
Eylea sales fell and missed expectations in the U.S.
Via
Investor's Business Daily
What's Going On With Immix Biopharma Stock Today
May 03, 2023
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
Via
Benzinga
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
May 03, 2023
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several...
Via
Benzinga
Is This Big Pharma Stock a Buy for Dividend Investors?
April 27, 2023
The Swiss pharmaceutical giant possesses a tremendous product pipeline.
Via
The Motley Fool
Why Novartis Stock Is Trading Higher Today
April 25, 2023
Via
Benzinga
Earnings Preview: Novartis
April 24, 2023
Via
Benzinga
Johnson & Johnson Ignites CAR-T Ambitions With Licensing Pact With Cellular Biomedicine
May 02, 2023
Johnson & Johnson's (NYSE: JNJ) pharma unit Janssen
Via
Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
May 02, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
April 28, 2023
Microsoft, Meta, Cloudflare and Crocs were among the many big movers.
Via
Investor's Business Daily
New York Rep. Daniel Goldman Bought Over $50K Worth of Novartis Stock: Here's What You Should Know
April 18, 2023
Via
Benzinga
Rare Blood Disorder Treatment Breakthrough: Novartis' Candidate Improves Hemoglobin To Near-Normal Levels
April 26, 2023
Novartis AG (NYSE: NVS) released detailed
Via
Benzinga
After Q1 Review, Novartis Narrows R&D Pipeline To Prioritize High-Value Transformative Medicines
April 25, 2023
In its Q1 FY23 earnings release, Novartis AG (NYSE: NVS) announced cutting its pipeline by around 10% as CEO Vas Narasimhan's campaign to turn it into a "pure-play" drugmaker goes full steam.
Via
Benzinga
Novartis Extends Breakout As Three Key Drivers Lead To A Beat-And-Raise
April 25, 2023
Novartis stock popped on its guidance boost early Tuesday after the company beat first-quarter expectations.
Via
Investor's Business Daily
3 Top Biotech Stocks Defying the Bear Market
April 25, 2023
All three companies have therapies with strong sales potential.
Via
The Motley Fool
Why Legend Biotech Stock Is Having Its Best Month Yet
April 25, 2023
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.
Via
MarketBeat
Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know
April 13, 2023
Via
Benzinga
Novartis Says Relapsing Multiple Sclerosis Patients Remained Free From Disease Progression For Up Five Years With Kesimpta Treatment
April 20, 2023
Via
Benzinga
Why Shares of Legend Biotech Jumped Wednesday
April 19, 2023
A leaked abstract on a phase 3 trial for the company's multiple myeloma drug Carvykti gave the stock a jolt.
Via
The Motley Fool
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Presents Innovative Pipeline of Nanosized Antibody Treatments at Bio-Europe Spring Conference in Switzerland
April 18, 2023
Via
Investor Brand Network
2 Best Biotech Stocks to Buy for the Long Haul
April 17, 2023
These two are among the largest pharma companies in the world.
Via
The Motley Fool
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
April 16, 2023
You have to be patient when investing in pharma stocks. But sometimes the risk and the wait aren't worth the rewards.
Via
InvestorPlace
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
April 13, 2023
Via
Benzinga
Alzheimer's Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments — Could Regulatory T-Cells (Tregs) Be The Answer?
April 13, 2023
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or...
Via
Benzinga
Trillions In Biotech Stock Gains Trace Back To This Financier
April 13, 2023
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider.
Via
Investor's Business Daily
Epic Growth Story Predicted for Pharmaceutical Drug Delivery Market's Future: Johnson & Johnson, Novartis International, Merck
April 12, 2023
Stay up-to-date with Pharmaceutical Drug Delivery Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher
April 12, 2023
Tilray Brands moves lower on mixed results, but the bottom may be in, with positive FCF expected this quarter. The long-term catalyst is US legalization.
Via
MarketBeat
Topics
Cannabis
Exposures
Cannabis
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
April 10, 2023
Via
Benzinga
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket
April 10, 2023
Shares are closing in on a buy point out of a consolidation.
Via
Investor's Business Daily
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
45
46
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.